ArticleMolecular biotechnology2026
A New Small and Resilient Nucleic Acid-Binding Protein from Nanoarchaeum equitans.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleic acid-binding proteins (NBPs) are essential biomolecules in all organisms. They play an important role in gene regulation and expression in cells. One type of these proteins is DNA- and RNA-binding proteins, known as DRBPs. In recent years, research has started to focus more on this particular group and new DRBPs have been identified successively. Their special dual-binding abilities are used in biotechnology and medicine. They can be applied for gene editing and drug development in treating such diseases as cancer. One of the NBP is Neq150, which comes from the Archaea strain Nanoarchaeum equitans. In our study, we purified the recombinant Neq150 with IMAC chromatography and assessed its binding ability to various forms of nucleic acids with EMSA. Thus, we concluded that Neq150 can be classified as a DRBP. Moreover, it exhibits thermostability at high temperatures (3 h at 99 °C) and significant long-term stability under various conditions. These results indicate that the Neq150 protein is a promising candidate for many applications in biotechnology and molecular biology, for example, as an auxiliary protein. The fusion of the DNA polymerase with another NBP protein from N. equitans (NeqSSB) has been previously well characterized, showing potential for similar possible applications for the Neq150.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.